These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 11886464)
21. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25). Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B; Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606 [TBL] [Abstract][Full Text] [Related]
22. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610 [TBL] [Abstract][Full Text] [Related]
23. Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study. Ferri Grazzi E; Hawes C; Camp C; Hinds D; O'Hara J; Burke T Health Qual Life Outcomes; 2024 Jul; 22(1):58. PubMed ID: 39075533 [TBL] [Abstract][Full Text] [Related]
24. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A. Sun HL; McIntosh KA; Squire SJ; Yang M; Bartholomew C; Gue DS; Camp PG; Jackson SC Haemophilia; 2017 Nov; 23(6):877-883. PubMed ID: 28851133 [TBL] [Abstract][Full Text] [Related]
25. Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis. Lalezari S; Acquadro M; de Bock E; Lambert J; Simpson ML Adv Ther; 2020 Jun; 37(6):2763-2776. PubMed ID: 32410165 [TBL] [Abstract][Full Text] [Related]
26. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382 [TBL] [Abstract][Full Text] [Related]
27. Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience. Osooli M; Steen Carlsson K; Astermark J; Berntorp E Haemophilia; 2017 Sep; 23(5):e403-e408. PubMed ID: 28758324 [TBL] [Abstract][Full Text] [Related]
28. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Khawaji M; Astermark J; Berntorp E Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195 [TBL] [Abstract][Full Text] [Related]
30. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan. Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742 [TBL] [Abstract][Full Text] [Related]
31. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment. Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299 [TBL] [Abstract][Full Text] [Related]
32. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282 [TBL] [Abstract][Full Text] [Related]
33. Haemophilia prophylaxis: a model and future directions in Jordan. Awidi A; Faouri S; Kiswani BA; Al-Sweedan S; Albarqawi M; Bsoul N; Haddadin I; Al-Falah M; Telfah A; Hermans C Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s343-4. PubMed ID: 24120588 [No Abstract] [Full Text] [Related]
34. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. O'Hara S; Castro FA; Black J; Chaplin S; Ruiz L; Hampton RJ; Sima CS; O'Hara J Haemophilia; 2021 Jan; 27(1):113-119. PubMed ID: 33084176 [TBL] [Abstract][Full Text] [Related]
35. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825 [TBL] [Abstract][Full Text] [Related]
36. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. De Moerloose P; Urbancik W; Van Den Berg HM; Richards M Haemophilia; 2008 Sep; 14(5):931-8. PubMed ID: 18684125 [TBL] [Abstract][Full Text] [Related]
37. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016 [TBL] [Abstract][Full Text] [Related]
38. [Quality of life of young patients with haemophilia in Europe]. Bullinger M; Gringeri A; von Mackensen S Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jun; 51(6):637-45. PubMed ID: 18481032 [TBL] [Abstract][Full Text] [Related]
39. The role of physical medicine and rehabilitation in haemophiliac patients. De la Corte-Rodriguez H; Rodriguez-Merchan EC Blood Coagul Fibrinolysis; 2013 Jan; 24(1):1-9. PubMed ID: 23103725 [TBL] [Abstract][Full Text] [Related]
40. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]